Aspirin, salicylates, and cancer

Elwood, Peter Creighton, Gallagher, Alison M., Duthie, Garry G., Mur, Luis A. J. and Morgan, Gareth 2009. Aspirin, salicylates, and cancer. The Lancet 373 (9671) , pp. 1301-1309. 10.1016/S0140-6736(09)60243-9

Full text not available from this repository.

Abstract

Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-infl ammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefi t of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Elsevier
ISSN:	0140-6736
Last Modified:	10 Jun 2023 01:14
URI:	https://orca.cardiff.ac.uk/id/eprint/25737

Citation Data

Cited 249 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item